Drug news
Advisory Committee date for review of tisagenlecleucel-T (CTL 019) to treat relapsed refractory B-cell acute lymphoblastic leukemia . - Novartis
The FDA has announced the first advisory committee meeting to review a chimeric antigen receptor (CAR)-T therapy. The Oncologic Drugs Advisory Committee will review Novartis' tisagenlecleucel-T (CTL 019) during a meeting on 12 July 2017. Novartis is seeking approval for the cell therapy for relapsed refractory B-cell acute lymphoblastic leukemia (ALL) in pediatric and young adult patients. It could be the first CAR-T therapy to reach the market.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins